Construction of a Novel Immune-Related LncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2021 Sep 13

PMID 34512816

Citations 7

Authors

Jian-Xuan Sun

Qi-Dong Xia

Chen-Qian Liu

Jin-Zhou Xu

Yang Xun

Jun-Lin Lu

Jia Hu

Shao-Gang Wang

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC) is one of the most common aggressive malignant tumors in the urinary system, among which the clear cell renal cell carcinoma (ccRCC) is the most common subtype. The immune-related long noncoding ribonucleic acids (irlncRNAs) which are abundant in immune cells and immune microenvironment (IME) have potential significance in evaluating the prognosis and effects of immunotherapy. The signature based on irlncRNA pairs and independent of the exact expression level seems to have a latent predictive significance for the prognosis of patients with malignant tumors but has not been applied in ccRCC yet.

Method: In this article, we retrieved The Cancer Genome Atlas (TCGA) database for the transcriptome profiling data of the ccRCC and performed coexpression analysis between known immune-related genes (ir-genes) and lncRNAs to find differently expressed irlncRNA (DEirlncRNA). Then, we adopted a single-factor test and a modified LASSO regression analysis to screen out ideal DEirlncRNAs and constructed a Cox proportional hazard model. We have sifted 28 DEirlncRNA pairs, 12 of which were included in this model. Next, we compared the area under the curve (AUC), found the cutoff point by using the Akaike information criterion (AIC) value, and distinguished the patients with ccRCC into a high-risk group and a low-risk group using this value. Finally, we tested this model by investigating the relationship between risk score and survival, clinical pathological characteristics, cells in tumor immune microenvironment, chemotherapy, and targeted checkpoint biomarkers.

Results: A novel immune-related lncRNA pair signature consisting of 12 DEirlncRNA pairs was successfully constructed and tightly associated with overall survival, clinical pathological characteristics, cells in tumor immune microenvironment, and reactiveness to immunotherapy and chemotherapy in patients with ccRCC. Besides, the efficacy of this signature was verified in some commonly used clinicopathological subgroups and could serve as an independent prognostic factor in patients with ccRCC.

Conclusions: This signature was proven to have a potential predictive significance for the prognosis of patients with ccRCC and the efficacy of immunotherapy.

Citing Articles

A novel oxidative-stress related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma.

Zhang Y, Zhou G, Shi W, Shi W, Hu M, Kong D Sci Rep. 2023; 13(1):5740.

PMID: 37029263 PMC: 10082204. DOI: 10.1038/s41598-023-32891-z.

Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.

Deng Y, Guo K, Tang Z, Feng Y, Cai S, Ye J Front Immunol. 2022; 13:1046790.

PMID: 36505457 PMC: 9730408. DOI: 10.3389/fimmu.2022.1046790.

Prognostic significance and identification of basement membrane-associated lncRNA in bladder cancer.

Feng L, Yang J, Zhang W, Wang X, Li L, Peng M Front Oncol. 2022; 12:994703.

PMID: 36300088 PMC: 9590283. DOI: 10.3389/fonc.2022.994703.

A novel marker based on necroptosis-related long non-coding RNA for forecasting prognostic in patients with clear cell renal cell carcinoma.

Lv J, Xu Q, Wu G, Hou J, Yang G, Tang C Front Genet. 2022; 13:948254.

PMID: 36212132 PMC: 9532702. DOI: 10.3389/fgene.2022.948254.

N7-methylguanosine-related lncRNAs: Distinction between hot and cold tumors and construction of predictive models in colon adenocarcinoma.

Cheng Z, Wang J, Xu Y, Jiang T, Xue Z, Li S Front Oncol. 2022; 12:951452.

PMID: 36185235 PMC: 9520617. DOI: 10.3389/fonc.2022.951452.

References

Qi-Dong X, Yang X, Lu J, Liu C, Sun J, Li C . Development and Validation of a Nine-Redox-Related Long Noncoding RNA Signature in Renal Clear Cell Carcinoma. Oxid Med Cell Longev. 2021; 2020:6634247. PMC: 7781722. DOI: 10.1155/2020/6634247. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X . Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Mol Ther Nucleic Acids. 2020; 22:937-947. PMC: 7670249. DOI: 10.1016/j.omtn.2020.10.002. View

Bhan A, Soleimani M, Mandal S . Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965-3981. PMC: 8330958. DOI: 10.1158/0008-5472.CAN-16-2634. View

Motzer R, McCann L, Deen K . Pazopanib versus sunitinib in renal cancer. N Engl J Med. 2013; 369(20):1970. DOI: 10.1056/NEJMc1311795. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

Speiser D, Ho P, Verdeil G . Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016; 16(10):599-611. DOI: 10.1038/nri.2016.80. View

Turajlic S, Swanton C, Boshoff C . Kidney cancer: The next decade. J Exp Med. 2018; 215(10):2477-2479. PMC: 6170181. DOI: 10.1084/jem.20181617. View

Motzer R, Hutson T, Glen H, Michaelson M, Molina A, Eisen T . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16(15):1473-1482. DOI: 10.1016/S1470-2045(15)00290-9. View

10.

Chen Y, Luo T, Xu S, Chen C, Sun Y, Lin L . An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma. Cancer Med. 2021; 10(7):2268-2285. PMC: 7982618. DOI: 10.1002/cam4.3756. View

11.

Cheng M, Sun L, Huang K, Yue X, Chen J, Zhang Z . A Signature of Nine lncRNA Methylated Genes Predicts Survival in Patients With Glioma. Front Oncol. 2021; 11:646409. PMC: 8019920. DOI: 10.3389/fonc.2021.646409. View

12.

Atianand M, Caffrey D, Fitzgerald K . Immunobiology of Long Noncoding RNAs. Annu Rev Immunol. 2017; 35:177-198. PMC: 6449690. DOI: 10.1146/annurev-immunol-041015-055459. View

13.

Lv Y, Lin S, Hu F, Ye Z, Zhang Q, Wang Y . Landscape of cancer diagnostic biomarkers from specifically expressed genes. Brief Bioinform. 2019; 21(6):2175-2184. DOI: 10.1093/bib/bbz131. View

14.

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

15.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

16.

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

17.

Chen M, Wei X, Shi X, Lu L, Zhang G, Huang Y . LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA. Cancer Biol Med. 2021; . PMC: 8185866. DOI: 10.20892/j.issn.2095-3941.2020.0209. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

19.

Vuong L, Kotecha R, Voss M, Hakimi A . Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2019; 9(10):1349-1357. PMC: 6774890. DOI: 10.1158/2159-8290.CD-19-0499. View

20.

Chevrier S, Levine J, Zanotelli V, Silina K, Schulz D, Bacac M . An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017; 169(4):736-749.e18. PMC: 5422211. DOI: 10.1016/j.cell.2017.04.016. View